<DOC>
	<DOC>NCT00639158</DOC>
	<brief_summary>The primary purpose of this study is to compare the safety and efficacy of ABT-335 (investigational drug) coadministered with atorvastatin and ezetimibe to atorvastatin coadministered with ezetimibe in subjects with abnormal lipid (fat) levels in the blood.</brief_summary>
	<brief_title>Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Fenofibric acid</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Subjects with mixed dyslipidemia (trigylcerides, &gt; or = to 150 mg/dL to &lt; 400 mg/dL; HDLC &lt; 40 mg/dL for males, &lt; 50 mg/dL for females; LDLC, &gt; or = to 130 mg/dL). Subjects must agree to use adequate birth control methods and to adhere to the American Heart Association (AHA) Diet. Subjects with unstable or uncontrolled medical conditions considered inappropriate in a clinical trial. Subjects with an unstable dose of medications or receiving Coumadin, oral, intravenous or intramuscular cyclosporine, statins, or certain other medications. Women who are pregnant or plan on becoming pregnant, or women who are lactating.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>